Auranofin and its analogs as prospective agents for the treatment of colorectal cancer

Abstract

Today colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. This disease is poorly chemo-sensitive toward the existing medical treatments so that new and more effective therapeutic agents are urgently needed and intensely sought. Platinum drugs, oxaliplatin in particular, were reported to produce some significant benefit in CRC treatment, triggering the general interest of medicinal chemists and oncologists for metal-based compounds as candidate anti-CRC drugs. Within this frame, gold compounds and, specifically, the established antiarthritic drug auranofin with its analogs, form a novel group of promising anticancer agents. Owing to its innovative mechanism of action and its favorable pharmacological profile, auranofin together with its derivatives are proposed here as novel experimental agents for CRC treatment, capable of overcoming resistance to platinum drugs. Some encouraging results in this direction have already been obtained. A few recent studies demonstrate that the action of auranofin may be further potentiated through the preparation of suitable pharmaceutical formulations capable of protecting the gold pharmacophore from unselective reactivity or through the design of highly synergic drug combinations. The perspectives of the research in this field are outlined.

Keywords

Auranofin / CRC / colorectal cancer / metallodrugs / anticancer agents / gold / gold-based drugs

References

[1] Ferlizza E,Sgarzi M,Lauriola M.The roadmap of colorectal cancer screening.Cancers (Basel)2021;13:1101 PMCID:PMC7961708

[2] Xie YH,Fang JY.Comprehensive review of targeted therapy for colorectal cancer.Signal Transduct Target Ther2020;5:22 PMCID:PMC7082344

[3] Siegel RL,Jemal A.Cancer statistics, 2019.CA A Cancer J Clin2018;69:7-34

[4] Vatandoust S,Karapetis CS.Colorectal cancer: metastases to a single organ.World J Gastroenterol2015;21:11767-76 PMCID:PMC4631975

[5] Valderrama-Treviño AI,Ceballos-Villalva JC.Hepatic metastasis from colorectal cancer.Euroasian J Hepatogastroenterol2017;7:166-75 PMCID:PMC5670263

[6] Petrelli F,Lonati V.A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer.Int J Colorectal Dis2015;30:447-57

[7] Mukkamalla SKR,Somasundar PS.Adjuvant chemotherapy and tumor sidedness in stage ii colon cancer: analysis of the national cancer data base.Front Oncol2020;10:568417 PMCID:PMC7523086

[8] Tamura T,Kadoyama K.Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.Int J Med Sci2011;8:406-12 PMCID:PMC3133846

[9] Larsson PA,Gustavsson B,Glimelius B.Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.Acta Oncol1996;35:207-12

[10] Tomlinson SK,Higgs V.Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer - a phase II study.BMC Cancer2002;2:1-7 PMCID:PMC113263

[11] Françoso A.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.Drug Des Devel Ther2017;11:177-84 PMCID:PMC5241129

[12] Laffer U,Aeberhard P.Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial.Int J Colorectal Dis2008;23:1233-41

[13] Biller LH.Diagnosis and treatment of metastatic colorectal cancer: a review.JAMA2021;325:669-85

[14] Shinozaki E,Kagawa Y.Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: a retrospective observational study using an administrative database.PLoS One2021;16:e0246160 PMCID:PMC7870079

[15] Köberle B.Platinum complexes in colorectal cancer and other solid tumors.Cancers (Basel)2021;13:2073 PMCID:PMC8123298

[16] Tomicic MT,Rasenberger B,Christmann M.Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6.Arch Toxicol2019;93:2265-77

[17] Mirakhorli M,Rahman SA,Abdullah S.Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy.Oncol Lett2012;4:893-7 PMCID:PMC3499608

[18] Huang MY,Lin CH.Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.J Surg Oncol2013;108:457-64

[19] Bruno PM,Park GY.A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.Nat Med2017;23:461-71 PMCID:PMC5520548

[20] Hartmann JT.Toxicity of platinum compounds.Expert Opin Pharmacother2003;4:889-901

[21] McQuade RM,Abalo R,Nurgali K.Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments.Front Pharmacol2016;7:414 PMCID:PMC5093116

[22] Oun R,Wheate NJ.The side effects of platinum-based chemotherapy drugs: a review for chemists.Dalton Trans2018;47:6645-53

[23] Martinez-Balibrea E,Ginés A.Tumor-related molecular mechanisms of oxaliplatin resistance.Mol Cancer Ther2015;14:1767-76

[24] Gamberi T,Messori L.Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds.Coord Chem Rev2021;438:213905

[25] Fernández-moreira V,Gimeno MC.Anticancer properties of gold complexes with biologically relevant ligands.Pure Appl Chem2019;91:247-69

[26] Liu W.Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.Chem Soc Rev2013;42:755-73

[27] Kim JH,Parkin S,Sullivan PG.Anticancer gold(iii)-bisphosphine complex alters the mitochondrial electron transport chain to induce in vivo tumor inhibition.Chem Sci2021;12:7467-79 PMCID:PMC8171344

[28] Rigobello MP,Boscolo R.Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative.Br J Pharmacol2002;136:1162-8 PMCID:PMC1573451

[29] Citta A,Mohr F.Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights.Metallomics2013;5:1006-15

[30] Gordon AN,Sun S.Doxil Study 30-49 InvestigatorsLong-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.Gynecol Oncol2004;95:1-8

[31] Rackham O,Leedman PJ,Filipovska A.A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria.Biochem Pharmacol2007;74:992-1002

[32] Messori L,Innocenti A,Franchi M.Molecular recognition of metal complexes by DNA: a comparative study of the interactions of the parent complexes [PtCl(TERPY)]Cl and [AuCl(TERPY)]Cl2 with double stranded DNA.Bioinorg Chem Appl2005;:239-53

[33] Alsaeedi MS,Hussien MA,Humphrey MG.DNA-binding and anticancer activity of binuclear gold(I) alkynyl complexes with a phenanthrenyl bridging ligand.Molecules2020;25:1033 PMCID:PMC7179095

[34] Ott I.Non platinum metal complexes as anti-cancer drugs.Arch Pharm (Weinheim)2007;340:117-26

[35] Sadler PJ.The chemistry of gold drugs.Met Based Drugs1994;1:107-44 PMCID:PMC2364882

[36] Shaw CF.Chrysotherapy:gold-drug metabolism and immunochemistry. In: Clarke MJ, Sadler PJ, editors. Metallopharmaceuticals II. Berlin: Springer Berlin Heidelberg; 1999. p. 187-216.

[37] Marzano C,Folda A,Bindoli A.Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.Free Radic Biol Med2007;42:872-81

[38] Harbut MB,Luo X.Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.Proc Natl Acad Sci U S A2015;112:4453-8 PMCID:PMC4394260

[39] Thangamani S,Mohammad H.Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway.Front Cell Infect Microbiol2017;7:4 PMCID:PMC5241286

[40] Díez-Martínez R,Manzano M.Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections.Sci Rep2016;6:19525 PMCID:PMC4726118

[41] Onodera T,Kawada M.Potential anticancer activity of auranofin.Chem Pharm Bull (Tokyo)2019;67:186-91

[42] Raninga PV,Sinha D.Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.Int J Cancer2020;146:123-36

[43] Menconi A,Massai L.Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles.Biometals2021;34:867-79 PMCID:PMC8313464

[44] Mirabelli CK,Sung CM,Muirhead K.Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models.Cancer Res1985;45:32-9

[45] Zoppi C,Pratesi A.ESI MS studies highlight the selective interaction of Auranofin with protein free thiols.Dalton Trans2020;49:5906-13

[46] Tolbatov I,Marchetti L.Mechanistic insights into the anticancer properties of the auranofin analog Au(PEt₃)I: a theoretical and experimental study.Front Chem2020;8:812 PMCID:PMC7531625

[47] Hossain MF,Klein C.Molecular basis for the interactions of human thioredoxins with their respective reductases.Oxid Med Cell Longev2021;2021:6621292 PMCID:PMC8189816

[48] Magherini F,Bini L.Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.J Biol Inorg Chem2010;15:573-82

[49] Yue S,Liu H.Recent advances of gold compounds in anticancer immunity.Front Chem2020;8:543 PMCID:PMC7338717

[50] Freire Boullosa L,Flieswasser T.Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.Redox Biol2021;42:101949 PMCID:PMC8113045

[51] Marzo T,Gabbiani C.Auranofin, Et₃PAuCl, and Et₃PAuI are highly cytotoxic on colorectal cancer cells: a chemical and biological study.ACS Med Chem Lett2017;8:997-1001 PMCID:PMC5641946

[52] Cirri D,Massai L.Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin.Biometals2019;32:939-48

[53] Marzo T,Hrabina O.cis-Pt I2(NH3)2: a reappraisal.Dalton Trans2015;44:14896-905

[54] Cirri D,Gabbiani C.PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features.Dalt Trans2017;46:3311-7

[55] Noordhuis P,van de Born K,Peters GJ.Coexisting molecular determinants of acquired oxaliplatin resistance in human colorectal and ovarian cancer cell lines.Int J Mol Sci2019;20:3619 PMCID:PMC6696456

[56] Han Y,Zhang Y.Synergy between Auranofin and Celecoxib against colon cancer in vitro and in vivo through a novel redox-mediated mechanism.Cancers (Basel)2019;11:931 PMCID:PMC6678510

[57] Bradley C,Warren JL,Zeruto C.Trends in chemotherapy-related treatment of advanced-stage colorectal (CRC) cancer.J Clin Oncol2013;31:258-258

[58] Arena S,Durinikova E.A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin.Clin Cancer Res2020;26:1372-84

[59] Nardon C,Fregona D.Beyond platinums: gold complexes as anticancer agents.Anticancer Res2014;34:487-92